These include Cancer Antigen 125 (CA125) for ovarian cancer (17, 35), cancer antigen 19-9 (CA 19-9) for pancreatic cancer (36), cancer antigen 15-3 (CA 15-3) for breast cancer (37), prostate-specific antigen (PSA) for prostate cancer (15), and carcinoembryonic antigen (CEA) increases in colorectal, bladder, breast, pancreatic and lung cancer (38). This evidence concerns the gene CEACAM5 and familial pancreatic carcinoma.